Papyrus Therapeutics, Inc. is a developing biopharmaceutical company that focuses on creating innovative extracellular tumor suppressor treatments for cancer. It was co-founded by Professor Hani Gabra, co-founder and CSA, who is a globally respected figure in ovarian cancer and translational medical oncology, with a portfolio of over 200 publications and 20,000 references, boasting an Hirsch Index of 64. Another co-founder and CEO, Dr. Paul Blake, brings over 30 years of experience in drug development and has been involved in multiple NDA/MAA approvals while working for Zeneca (now AZ), SB (now GSK), Cephalon (now Teva), Oxford BioMedica, and Heron Therapeutics.
Papyrus Therapeutics
Headquarters
United States of America